Overview
P21 (also written P-021 or P-021 compound) is a small synthetic peptidomimetic developed by the Iqbal lab at New York State Institute for Basic Research, designed as a fragment of ciliary neurotrophic factor (CNTF) that retains neurogenic activity while crossing the blood–brain barrier. Rodent studies in models of Alzheimer's disease, traumatic brain injury, and neonatal brain injury have shown enhanced hippocampal neurogenesis, restored cognitive performance on water-maze and novel-object tests, and reduced hyperphosphorylated tau pathology. None of this has translated to a published human trial. Community marketing for nootropic stacking, particularly via vendors that pair it with dihexa, runs ahead of the evidence by an extreme margin.
Mechanism
Mimics a neurogenic fragment of CNTF (ciliary neurotrophic factor) but is small enough to cross the blood–brain barrier. Activates leptin/JAK/STAT and BDNF-related signaling pathways implicated in adult hippocampal neurogenesis, enhances neurite outgrowth, and reduces tau hyperphosphorylation in animal AD models. The exact receptor target in humans is incompletely characterized.
Evidence by indication
We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.
Cognitive enhancement / nootropic in healthy adults
Mechanistic extrapolation. There is no human evidence of cognitive benefit in healthy adults — the rodent studies were all in disease models, not normal animals.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Neurogenesis / cognitive enhancement (animal models)
Multiple rodent studies (Bolognin/Iqbal 2014, Khatoon 2015) demonstrate hippocampal neurogenesis and cognitive recovery in AD and TBI models. Effect sizes are striking but confined to animals; no published human study has reported results.
Alzheimer's disease
Patent literature and preclinical work position P21 as an AD candidate. No human trial has reached publication. Community use as an AD intervention is unsupported by clinical evidence.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Studied dose ranges
The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.
Community dosing varies enormously — vendor-recommended ranges run from 100 mcg/day to >1 mg/day with no published human PK data to anchor any of it. The dose range listed here is descriptive of community practice, not endorsed.
Contraindications
- Any active malignancy (CNTF / leptin / JAK-STAT signaling overlaps with proliferation pathways; safety unknown)
- Pregnancy and breastfeeding
- Pediatric use (any animal-only compound is inappropriate for children outside formal trials)
- Use during active immunotherapy or chemotherapy (interaction with disease biology unknown)
- Known hypersensitivity
Reported side effects
- Unknown in humans — no published human safety data
- Anecdotal community reports: headache, irritability, sleep disturbance, anxiety; uncontrolled and unverified
- Theoretical: any neurogenic compound has uncharacterized long-term effects on adult brain plasticity and seizure threshold
Reconstitution & storage
Vendor preparations vary; powder forms reconstituted with bacteriostatic water or sterile saline depending on route. Oral and sublingual community use does not require reconstitution.
Storage. Vendor-dependent. Powder forms typically refrigerated; oral preparations at room temperature, dry, protected from light.
Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.
Editorial note
DRAFT — pending Wayne's review. Same editorial posture as dihexa: animal-only evidence + aggressive community marketing. The science is interesting; the marketing is not. Tier 4 across the board, no claim of nootropic benefit in humans.
Citations
- [1]An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptideBolognin S, Blanchard J, Wang X, et al. (Iqbal K, group) · Acta Neuropathologica · 2014 · PMID 24710115Anchor preclinical demonstration of P21's procognitive effects in a rat AD model. Tier 4 because no human translation exists.View source